{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:41:59Z","timestamp":1780616519092,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpcardiol.2024.102882","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T14:53:51Z","timestamp":1729349631000},"page":"102882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Doxorubicin and cyclophosphamide mode of chemotherapy\u2013related cardiomyopathy: Review of preclinical model"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-8355","authenticated-orcid":false,"given":"Ashot","family":"Avagimyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Kakturskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.cpcardiol.2024.102882_bib0001","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks collaborators. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102882_bib0003","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CEJ.0000000000000594","article-title":"Progress in cancer mortality, incidence, and survival: a global overview","volume":"29","author":"Santucci","year":"2020","journal-title":"Eur J Cancer Prev"},{"issue":"17","key":"10.1016\/j.cpcardiol.2024.102882_bib0004","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102882_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100909","article-title":"Anthracycline associated disturbances of cardiovascular homeostasis","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2024.102882_bib0006","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101591","article-title":"State of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics","volume":"48","author":"Abdul-Rahman","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20538\/1682-0363-2022-4-44-53","article-title":"Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases","volume":"21","author":"Grakova","year":"2022","journal-title":"Bull Siber Med"},{"issue":"41","key":"10.1016\/j.cpcardiol.2024.102882_bib0009","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102882_bib0010","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.15829\/1560-4071-2023-5452","article-title":"Cardiovascular prevention 2022. Russian national guidelines","volume":"28","author":"Boytsov","year":"2023","journal-title":"Russ J Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0011","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102882_bib0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.35401\/2541-9897-2024-9-2-8-15","article-title":"Speckle-tracking echocardiography in assessment of breast cancer therapy-related subclinical cardiac dysfunction","author":"Akbalaeva","year":"2024","journal-title":"Innov Med Kuban"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102882_bib0013","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131331","article-title":"Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy","volume":"391","author":"Avagimyan","year":"2023","journal-title":"Int J Cardiol"},{"issue":"322","key":"10.1016\/j.cpcardiol.2024.102882_bib0015","first-page":"158","article-title":"The impact of trimetazidine on the anthropometric parameters of doxorubicin-cyclophosphamide mode in chemotherapy-induced heart alteration","author":"Avagimyan","year":"2022","journal-title":"Georgian Med News"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102882_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.29001\/2073-8552-2022-37-2-105-111","article-title":"Trimetazidine as a modifier of doxorubicin + cyclophosphamide-induced hyperdyslipidemia","volume":"37","author":"Avagimyan","year":"2022","journal-title":"Siber J Clin Exp Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.35401\/2541-9897-2023-8-4-6-14","article-title":"Comparison of cardioprotective effects of dapagliflozin and trimetazidine in the model of doxorubicin-cyclophosphamide cardiotoxicity","author":"Avagimyan","year":"2023","journal-title":"Innov Med Kuban"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0018","first-page":"263","article-title":"Trimetazidine as a modifier of chemotherapy- induced endothelium homeostasis disturbances","volume":"14","author":"Avagimyan","year":"2022","journal-title":"Cardiol Belarus"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0019","first-page":"405","article-title":"Trimetazidine as a modifier of chemotherapy-induced cardiovascular redox-homeostasis disturbances","volume":"14","author":"Avagimyan","year":"2022","journal-title":"Cardiol Belarus"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102882_bib0020","first-page":"2148","article-title":"The essential strategies to mitigate cardiotoxicity caused by doxorubicin","volume":"13","author":"Chaulin","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1289384","article-title":"Melatonin mitigates oxidative damage induced by anthracycline: a systematic-review and meta-analysis of murine models","volume":"10","author":"Faggiano","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1241225","article-title":"Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity","volume":"10","author":"Chen","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102882_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18087\/cardio.2020.12.n1394","article-title":"Assessment of the dynamics of oxidative stress indicators and early markers of myocardial damage and dysfunction in patients with aggressive lymphoproliferative diseases during of anticancer therapy","volume":"60","author":"Antyufeeva","year":"2020","journal-title":"Kardiologiia"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0024","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","article-title":"Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches","volume":"22","author":"Sheibani","year":"2022","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","article-title":"Oxidative stress injury in doxorubicin-induced cardiotoxicity","volume":"307","author":"Songbo","year":"2019","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2024.107683","article-title":"Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury","author":"Avagimyan","year":"2024","journal-title":"Cardiovasc Pathol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0027","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbrc.2009.08.085","article-title":"NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis","volume":"388","author":"Gilleron","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"42","key":"10.1016\/j.cpcardiol.2024.102882_bib0028","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1093\/eurheartj\/ehac337","article-title":"A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity","volume":"43","author":"Lu","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.20538\/1682-0363-2017-3-127-136","article-title":"The cardiovascular system in patients with anthracycline cardiomiopathy","volume":"16","author":"Teplyakov","year":"2017","journal-title":"Bull Siberian Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102882_bib0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","article-title":"Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity","volume":"44","author":"Wu","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"28","key":"10.1016\/j.cpcardiol.2024.102882_bib0031","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102882_bib0032","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1016\/j.cpcardiol.2024.102882_bib0033","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1039\/D1TB00551K","article-title":"The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery","volume":"9","author":"Qin","year":"2021","journal-title":"J Mater Chem B"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102882_bib0034","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jjcc.2022.01.001","article-title":"The effects of doxorubicin on cardiac calcium homeostasis and contractile function","volume":"80","author":"Shinlapawittayatorn","year":"2022","journal-title":"J Cardiol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2024.102882_bib0035","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3390\/biomedicines10092197","article-title":"Calcium overload or underload? The effects of doxorubicin on the calcium dynamics in guinea pig hearts","volume":"10","author":"Wu","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0036","first-page":"785","article-title":"Relationship between chemotherapy and atrial fibrillation: clinical case","volume":"17","author":"Avagimyan","year":"2021","journal-title":"Ration Pharm. Cardiol."},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215992","article-title":"CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression","volume":"14","author":"Tscheschner","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0038","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","article-title":"Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats","volume":"85","author":"Sheibani","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102882_bib0039","first-page":"55","article-title":"Ultrastructural and echocardiographic assessment of chronic doxorubicin-induced cardiotoxicity in rats","volume":"75","author":"Babaei","year":"2020","journal-title":"Arch Razi Inst"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102882_bib0040","first-page":"1031","article-title":"Doxorubicin dose-dependent impact on physiological balance-a holistic approach in a rat model","volume":"12","author":"Afonso","year":"2023","journal-title":"Biology (Basel)"},{"issue":"9","key":"10.1016\/j.cpcardiol.2024.102882_bib0041","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.15829\/1560-4071-2021-4703","article-title":"\u0421onsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy","volume":"26","author":"Yu","year":"2021","journal-title":"Russian Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102882_bib0042","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40360-022-00569-3","article-title":"Cardioprotective effects of sodium thiosulfate against doxorubicin-induced cardiotoxicity in male rats","volume":"23","author":"Shekari","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102882_bib0044","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy - an update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0046","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000512771","article-title":"Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction","volume":"146","author":"Grakova","year":"2021","journal-title":"Cardiology"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151548","article-title":"Impact of doxorubicin treatment on the physiological functions of white adipose tissue","volume":"11","author":"Biondo","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102882_bib0048","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.3390\/molecules28114294","article-title":"Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity","volume":"28","author":"Sumneang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.cpcardiol.2024.102882_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115354","article-title":"SIRT3 attenuates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome via autophagy","volume":"207","author":"Sun","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102882_bib0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","article-title":"Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity","volume":"20","author":"Wei","year":"2020","journal-title":"Cardiovasc Toxicol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2024.102882_bib0051","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/cells8101224","article-title":"Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy","volume":"8","author":"Singla","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0052","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0053","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/pharmaceutics15041182","article-title":"Recent advances in mitochondrial fission\/fusion-targeted therapy in doxorubicin-induced cardiotoxicity","volume":"15","author":"Maneechote","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102882_bib0054","doi-asserted-by":"crossref","first-page":"41","DOI":"10.18699\/SSMJ20220304","article-title":"Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide","volume":"42","author":"Avagimyan","year":"2022","journal-title":"Sibirskij Nauchnyj Medicinskij Zhurnal (Siberian Sci Med J)"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102882_bib0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12012-019-09511-2","article-title":"Micheliolide protects against doxorubicin-induced cardiotoxicity in mice by regulating PI3K\/Akt\/NF-kB signaling pathway","volume":"19","author":"Kalantary-Charvadeh","year":"2019","journal-title":"Cardiovasc Toxicol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624005176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624005176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:50:37Z","timestamp":1732744237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624005176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0146280624005176"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102882","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxorubicin and cyclophosphamide mode of chemotherapy\u2013related cardiomyopathy: Review of preclinical model","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102882"}}